BFO
HRTX icon

Biltmore Family Office’s Heron Therapeutics HRTX Stock Holding History

Biltmore Family Office’s Portfolio HRTX Stock Details HRTX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$42.7K Hold
100,000
– – 0.01% 289
2026
Q1 		$80K Hold
100,000
– – 0.01% 264
2025
Q4 		$130K Hold
100,000
– – 0.02% 242
2025
Q3 		$126K Sell
100,000
-1,467
-1% -$2.33K 0.02% 225
2025
Q2 		$210K Hold
101,467
– – 0.04% 204
2025
Q1 		$223K Hold
101,467
– – 0.04% 195
2024
Q4 		$155K Buy
+101,467
New +$164K 0.03% 208
2023
Q4 		– Sell
-16,425
Closed -$16.9K – 237
2023
Q3 		$16.9K Hold
16,425
– – ﹤0.01% 213
2023
Q2 		$19.1K Buy
16,425
+125
+0.8% +$223 ﹤0.01% 210
2023
Q1 		$24.6K Buy
+16,300
New +$40.8K 0.01% 249

Other funds holding HRTX

RCMNY
Rubric Capital Management (New York) New York $10.9B AUM 70.31% 1-Year Est. Return
CC
Clearline Capital New York $1.68B AUM 53.07% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
VCIM
Velan Capital Investment Management Alpharetta, Georgia $164M AUM 542.31% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
TC
Tejara Capital London, United Kingdom $243M AUM 9.84% 1-Year Est. Return
TCM
Tang Capital Management San Diego, California $2.2B AUM 156.35% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
Millennium Management
Millennium Management New York $276B AUM 44.8% 1-Year Est. Return
JAM
JW Asset Management Miami Beach, Florida $320M AUM 140.1% 1-Year Est. Return

Biltmore Family Office's HRTX Position: Q2 2026 in Review

Biltmore Family Office held its Heron Therapeutics (HRTX) position steady in Q2 2026 at 100,000 shares worth $42.7K. The position accounts for 0.01% of the portfolio, ranked #289.

Biltmore Family Office first reported a position in HRTX in Q1 2023 and has held it in 10 quarters since. The position peaked at $223K in Q1 2025. 163 funds tracked by Wall St. Rank hold HRTX as of Q2 2026.

  • Biltmore Family Office held 100,000 shares of Heron Therapeutics worth $42.7K as of Q2 2026.
  • Biltmore Family Office left its Heron Therapeutics share count unchanged in Q2 2026.
  • Heron Therapeutics made up 0.01% of Biltmore Family Office's portfolio in Q2 2026, its #289 holding.
  • Biltmore Family Office first reported a position in Heron Therapeutics in Q1 2023 and has held it in 10 quarters since.
  • Biltmore Family Office's Heron Therapeutics position peaked at $223K in Q1 2025.
  • 163 funds tracked by Wall St. Rank held Heron Therapeutics as of Q2 2026.

Based on Biltmore Family Office's 13F filing for Q2 2026, filed 12 Aug 2026.